- 全部删除
- 您的购物车当前为空
D21-2393 subjects received a single-oral-dose of edoxaban 30-90 mg in each study occasion under fasting condition. Serial blood samples were collected to measure the plasma concentrations of edoxaban and its major active metabolite D21-2393. Meanwhile, PT, INR, aPTT were measured pre- and post-dose.
D21-2393 subjects received a single-oral-dose of edoxaban 30-90 mg in each study occasion under fasting condition. Serial blood samples were collected to measure the plasma concentrations of edoxaban and its major active metabolite D21-2393. Meanwhile, PT, INR, aPTT were measured pre- and post-dose.
规格 | 价格 | 库存 | 数量 |
---|---|---|---|
2 mg | ¥ 2,890 | 5日内发货 |
产品描述 | D21-2393 subjects received a single-oral-dose of edoxaban 30-90 mg in each study occasion under fasting condition. Serial blood samples were collected to measure the plasma concentrations of edoxaban and its major active metabolite D21-2393. Meanwhile, PT, INR, aPTT were measured pre- and post-dose. |
别名 | UNII-IV344R972X, Edoxaban 4-Carboxylic Acid, D21-2393, D21 2393 |
分子量 | 520.99 |
分子式 | C22H25ClN6O5S |
CAS No. | 834919-19-6 |
密度 | no data available |
存储 | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
溶解度信息 | DMSO: Soluble |
版权所有©2015-2024 TargetMol Chemicals Inc.保留所有权利.
评论内容